1.
|
Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0011004, ORTHO-PR-00-27-012, ORTHO-PR-01-27-003, NCI-G01-2002, NCT00022386
|
|
2.
|
Phase: Phase IV Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003541, NCT00216541
|
|
3.
|
Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003460, NCT00264095
|
|
4.
|
Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RWJPRI-EPO-CA-480, NCI-V96-0978
|
|
5.
|
Phase: Phase III Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-1996, E1996, NCT00003138
|
|
6.
|
Phase: Phase III Type: Supportive care Status: Completed Age: 18-80 Sponsor: NCI Protocol IDs: RPCI-DS-97-10, ORTHO-PR-96-27-004, NCI-G98-1394
|
|
7.
|
Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-97125, ORTHO-PR-96-27-031, RPCI-DS-97-38, NCI-G98-1436, NCT00003341
|
|
8.
|
Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-979253, NCI-P98-0133, 97-92-53, NCT00003600
|
|
9.
|
Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-9903, RTOG-DEV-1008, NCT00004917, RTOG-99-03
|
|
10.
|
Phase: Phase III Type: Treatment Status: Closed Age: 60 and under Sponsor: Pharmaceutical / Industry Protocol IDs: CAN-NCIC-MA21, AMGEN-CAN-NCIC-MA21, NCCTG-CAN-NCIC-MA21, BMS-CAN-NCIC-MA21, JANSSEN-ORTHO-CAN-NCIC-MA21, PFIZER-CAN-NCIC-MA21, NCIC-MA21, NCT00014222, SWOG-CAN-NCIC-MA21, MA21
|
|
11.
|
Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0191, CAN-NCIC-CX4, NCT00017004, CX4
|
|
12.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: EORTC-22996, ARO-EORTC-22996, EORTC-HN-22996, GORTEC-EORTC-22996, TROG-EORTC-22996, RHOG-EORTC-22996, GELCB-EORTC-22996, NCT00017277
|
|
13.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: CCCWFU-62299, CCCWFU-BG01-193, NCI-P01-0200, NCT00028938
|
|
14.
|
Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0201098, NCI-G02-2112, AMGEN-200101101, NCT00046982
|
|
15.
|
Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N02C2, NCT00058331
|
|
16.
|
Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1Z01, E1Z01, NCT00060398
|
|
17.
|
Phase: Phase III Type: Supportive care Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0306021, AMGEN-20030125, NCT00070382
|
|
18.
|
Phase: Phase III Type: Supportive care Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003223, NCT00210587
|
|
19.
|
Phase: Phase III Type: Treatment Status: Closed Age: 19 to 80 Sponsor: Other Protocol IDs: OEGRO54, NCT00348738
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: RPMI-DS-9429, NCI-T94-0072D, T94-0072
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 1 and over Sponsor: NCI Protocol IDs: SJCRH-NB-91, NCI-T91-0217D, T91-0217
|
|
22.
|
Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: E-1893, E1893
|
|
23.
|
Phase: Phase II Type: Treatment Status: Closed Age: adult Sponsor: NCI Protocol IDs: SWOG-9318
|
|
24.
|
Phase: Phase II Type: Treatment Status: Closed Age: not specified Sponsor: NCI Protocol IDs: UCCRC-8626, NU-V97N1, NCI-G97-1284
|
|
25.
|
Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: EORTC-06975, NCT00003681
|